ClinicalTrials.gg
CompletedNCT07149376Updated Nov 5, 2025

To Assess the Efficacy of a Toothpaste Containing 8% Arginine as Compared to Colgate Cavity Protection Toothpaste in the Reduction of Dentinal Hypersensitivity.

A Phase 3 interventional study of TOMs of Maine Sensitive SLS Free Xtra Fresh and Colgate Cavity protection toothpaste in Sensitivity, Tooth, sponsored by Colgate Palmolive. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies in Dentin Sensitivity with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Dentin Sensitivity · United States.

Enrollment
36th of 54
84 · median 120
Started
2025
with 5 others
Phase 3
8 of 57
none open now
Registered
49th of 57
by date
Lead sponsor
3 of 57
Colgate Palmolive

Among the 57 studies in Dentin Sensitivity with a site in United States, this one is the 36th largest by enrollment of the 54 interventional ones that give a count, is one of 6 that started in 2025, is one of 8 in phase 3, and was the 49th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

5 of the 57 studies in Dentin Sensitivity with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Dentin Sensitivity studies recruiting now, 6 (33%) set no upper age limit and 11 (61%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Dentin Sensitivity with a site in United States, or all of them as a file.
02

Study summary

The objective of this clinical investigation is to assess the efficacy of a toothpaste containing 8% arginine (Colgate-Palmolive Company, New York, NY, USA) as compared to a commercially available non-desensitizing toothpaste (Colgate Cavity Protection Toothpaste, Colgate-Palmolive Company, New York, NY, USA) in the reduction of dentinal hypersensitivity over an eight (8) week period.

03

Conditions studied

  • Sensitivity, Tooth

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign an Form;
  • Male or female 18 to 70 years of age, inclusive;
  • Be in good general health as determined by the study investigators;
  • Available for the eight (8) weeks duration of the study;
  • Must present two (2) sensitive teeth which must meet ALL of the following criteria:
  • Be anterior to the molars and demonstrating dentin exposure due to cervical erosion/abrasion and/or gingival recession;
  • Have a qualifying dentin response to tactile stimuli applied to the cervical surface (gingivo-facial 1/3) as defined by a response score between 10-50grams of force (Yeaple Probe, XiniX Research Inc. Portsmouth, NH, USA);
  • Have a qualifying dentin hypersensitivity response to air blast stimuli applied for one second to the cervical surface (gingivo-facial 1/3) as defined by a score of 2 or 3 on the Schiff Cold Air Sensitivity Scale.

Exclusion criteria

Exclusion Criteria:

  • Gross oral pathology, chronic disease, and/or history of allergies to any of the test products
  • Use of a desensitizing oral care product and/or recipient of any dental desensitizing treatment within the past three months prior to start of the study;
  • Advanced periodontal disease and/or treatment for periodontal disease (including surgery) within the past twelve months
  • Sensitive teeth with a mobility greater than one Teeth with extensive/defective restorations (including prosthetic crowns), suspected pulpitis, caries, cracked enamel, or used as abutments for removable partial dentures;
  • Current use of anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti- inflammatory drugs, or daily use of analgesics
  • Participation in any other oral clinical study for the duration of this study
  • Self-reported pregnancy and/or currently breastfeeding;
  • Allergies to oral care products, personal care consumer products, and/or their ingredients
  • Medical condition which prohibits not eating/drinking for 4 hours
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Active comparator
    Test 1 toothpaste

    During this clinical study, you will be assigned to one of the two study groups. You will be provided with a toothpaste and toothbrush for at home use. You will be instructed to brush your teeth twice daily for one (1) minute each time. You are to repeat the same procedures for the duration of the study.

    Device: TOMs of Maine Sensitive SLS Free Xtra Fresh

  • Active comparator
    Test 2 toothpaste

    During this clinical study, you will be assigned to one of the two study groups. You will be provided with a toothpaste and toothbrush for at home use. You will be instructed to brush your teeth twice daily for two (2) minute each time. You are to repeat the same procedures for the duration of the study.

    Drug: Colgate Cavity protection toothpaste

Interventions

  • DeviceTOMs of Maine Sensitive SLS Free Xtra Fresh

    Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for one (1) minute each time. For investigational use only by the study participant. Not for Sale.

  • Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for (2) two minutes each time. For investigational use only by the study participant.

06

What researchers measure

Primary outcomes

  1. Tactile stimulation by the Yeaple Probe

    Hypersensitivity defined by a response score in the range of 10-50 grams of force.

    Time frame: baseline, 3 day, 4 weeks, 8 weeks

  2. Air blast stimulation

    Jet of air delivered by a standard dental unit syringe at a measured temperature of 19-21°C (70°F \[± 3°F\]) \[hypersensitivity defined by a response score of 2 or 3 on the Schiff Cold Air Sensitivity Scale

    Time frame: baseline, 3 day, 4 weeks, 8 weeks

07

Study locations

1 site
  • FAR Oral and Systemic Health Consulting, Inc
    Costa Mesa, California 92627, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Oct 2025, 1 month.

Of 13 phase 3 interventional studies under Dentin Sensitivity, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 2, 2025
StartActual
Aug 18, 2025
Primary completionActual
Oct 14, 2025
CompletionActual
Oct 14, 2025
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07149376
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Aug 18, 2025
Primary completion
Oct 14, 2025
Completion
Oct 14, 2025
Last update
Nov 5, 2025

Study contacts

Farid Ayad
principal investigator · FAR ORAL SYSTEMIC HEALTH CONSULTING INC.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorophosphate

Start the discussion